Lyndsey Hale, MD
Neurology · San Antonio, TXNPI 1417241670
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Amgen at 45.3% of the total. 2025 is the largest year on record at $8,757, 5.2 times the $1,683 reported in 2019.
Across 204 payments — averaging $73.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- EMD Serono, Inc.$2K
- Sanofi$1K
- Biogen$897
- AstraZeneca$627
- Livanova USA, Inc.$606
- plus $3K from 27 others
Across 12 payments — averaging $2801.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$31K
- Roche Products Limited$2K
What the payments were for
- Consulting fees$6,35042%
- Speaking & faculty fees$360%
- Travel & lodging$3983%
- Food & beverage$8,16555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $6,774 |
| EMD Serono, Inc. | 35 | $1,557 |
| Sanofi | 16 | $1,174 |
| Biogen | 17 | $897 |
| AstraZeneca | 11 | $627 |
| Livanova USA, Inc. | 6 | $606 |
| Novartis | 26 | $532 |
| UCB, Inc. | 13 | $525 |
| TG Therapeutics, Inc. | 7 | $502 |
| Bristol Myers Squibb | 5 | $388 |
| Stryker | 2 | $164 |
| Lundbeck LLC | 3 | $163 |
| Biohaven Pharmaceuticals, Inc. | 6 | $163 |
| Alafair Biosciences, Inc. | 1 | $150 |
| Teva Pharmaceuticals USA, Inc. | 3 | $139 |
| Lilly USA, LLC | 5 | $77 |
| Mallinckrodt Enterprises LLC | 5 | $72 |
| Acadia Pharmaceuticals Inc | 5 | $71 |
| MDD US Operations, LLC | 3 | $42 |
| Johnson & Johnson | 2 | $39 |
| Acorda Therapeutics, Inc | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| GE HealthCare | 1 | $33 |
| Eisai Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Adamas Pharmaceuticals, Inc. | 1 | $20 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Greenwich Biosciences, Inc. | 1 | $17 |
| Corium, LLC | 1 | $16 |
| SK Life Science, Inc. | 1 | $13 |
| Argenx US, Inc. | 1 | $13 |
| Neurocrine Biosciences, Inc. | 1 | $12 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,949 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 13 | $1,694 |
| Gabapentin | 21 | $661 |
| Baclofen | 12 | $602 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Antonio
- Ann BassSan Antonio$1.7M
- Santiago RestrepoSan Antonio$532K
- Juan Ramirez CastanedaSan Antonio$456K
- Eleni VaouSan Antonio$236K
- Eric PappertSan Antonio$166K
- Arash SalardiniSan Antonio$125K
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.